贝伐单抗在难治性青光眼治疗中的临床应用。
Clinical use of Bevacizumab in treating refractory glaucoma.
作者信息
Popescu V, Pricopie S, Totir M, Iancu R, Yasyn S, Alexandrescu C
机构信息
Anatomy Department, "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania.
Department of Clinical Ophthalmology, University Emergency Hospital Bucharest, Romania.
出版信息
J Med Life. 2015 Jan-Mar;8(1):8-12.
Abstract
UNLABELLED
Bevacizumab is a recombinant humanized monoclonal antibody directed against vascular endothelial growth factor (VEGF). Though other VEGF inhibitors are being approved for the treatment of ophthalmological conditions, bevacizumab found its way into ophthalmology and clinical practice all around the world. The objective of this review is to present the ophthalmic dosage and administration pathways of bevacizumab in treating refractory glaucoma patients.
ABBREVIATIONS
VEGF = vascular endothelial growth factor, FDA = Food and Drug Administration, AMD = age-related macular degeneration.
摘要
未标注
贝伐单抗是一种针对血管内皮生长因子（VEGF）的重组人源化单克隆抗体。尽管其他VEGF抑制剂正在被批准用于治疗眼科疾病，但贝伐单抗已进入全球眼科和临床实践。本综述的目的是介绍贝伐单抗在治疗难治性青光眼患者中的眼科剂量和给药途径。
缩写
VEGF = 血管内皮生长因子，FDA = 食品药品监督管理局，AMD = 年龄相关性黄斑变性
相似文献
1
Clinical use of Bevacizumab in treating refractory glaucoma.贝伐单抗在难治性青光眼治疗中的临床应用。
J Med Life. 2015 Jan-Mar;8(1):8-12.
2
The efficiency of subconjunctival bevacizumab in refractory glaucoma - case report.结膜下注射贝伐单抗治疗难治性青光眼的疗效——病例报告
J Med Life. 2015 Jan-Mar;8(1):103-5.
3
Anti-vascular endothelial growth factor for control of wound healing in glaucoma surgery.抗血管内皮生长因子用于控制青光眼手术中的伤口愈合
Cochrane Database Syst Rev. 2016 Jan 15;2016(1):CD009782. doi: 10.1002/14651858.CD009782.pub2.
4
Pharmacogenetics in Model-Based Optimization of Bevacizumab Therapy for Metastatic Colorectal Cancer.基于遗传药理学的贝伐珠单抗治疗转移性结直肠癌的模型优化。
Int J Mol Sci. 2020 May 26;21(11):3753. doi: 10.3390/ijms21113753.
5
SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.玻璃体内注射阿柏西普、贝伐单抗和雷珠单抗的全身药代动力学和药效学
Retina. 2017 Oct;37(10):1847-1858. doi: 10.1097/IAE.0000000000001493.
6
Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients.私人保险和医疗保险优势计划患者眼科中抗血管内皮生长因子使用的趋势。
Ophthalmology. 2017 Mar;124(3):352-358. doi: 10.1016/j.ophtha.2016.10.036. Epub 2016 Nov 24.
7
[Evaluating the efficacy of anti-VEGF therapy in patients with exudative age-related macular degeneration and concomitant glaucoma].[评估抗血管内皮生长因子治疗渗出性年龄相关性黄斑变性合并青光眼患者的疗效]
Vestn Oftalmol. 2015 May-Jun;131(3):27-33. doi: 10.17116/oftalma2015131327-33.
8
Inhibition of vascular endothelial growth factor reduces scar formation after glaucoma filtration surgery.抑制血管内皮生长因子可减少青光眼滤过术后瘢痕形成。
Invest Ophthalmol Vis Sci. 2009 Nov;50(11):5217-25. doi: 10.1167/iovs.08-2662. Epub 2009 May 27.
9
Antivascular endothelial growth factors in age-related macular degeneration.年龄相关性黄斑变性中的抗血管内皮生长因子
Dev Ophthalmol. 2010;46:21-38. doi: 10.1159/000320007. Epub 2010 Aug 10.
10
Alternating Bi-Weekly Intravitreal Ranibizumab and Bevacizumab for Refractory Neovascular Age-Related Macular Degeneration with Pigment Epithelial Detachment.雷珠单抗和贝伐单抗交替双周玻璃体内注射治疗伴有色素上皮脱离的难治性新生血管性年龄相关性黄斑变性
Semin Ophthalmol. 2017;32(3):309-315. doi: 10.3109/08820538.2015.1072222. Epub 2015 Sep 4.
引用本文的文献
1
Bevacizumab and Sinus Venous Thrombosis: A Literature Review.贝伐单抗与静脉窦血栓形成：文献综述
Cureus. 2021 Nov 11;13(11):e19471. doi: 10.7759/cureus.19471. eCollection 2021 Nov.
2
Targeting Molecular Inflammatory Pathways in Granuloma as Host-Directed Therapies for Tuberculosis.针对肉芽肿中分子炎症途径的宿主导向疗法治疗结核病。
Front Immunol. 2021 Oct 20;12:733853. doi: 10.3389/fimmu.2021.733853. eCollection 2021.
3
A Systemic Lupus Erythematosus Patient With Febrile Neutropenia Developing After Intraocular Administration of Bevacizumab.一名系统性红斑狼疮患者在眼内注射贝伐单抗后发生发热性中性粒细胞减少症。
Arch Rheumatol. 2016 Jan 28;31(2):176-179. doi: 10.5606/ArchRheumatol.2016.5747. eCollection 2016 Jun.
4
The era of anti-vascular endothelial growth factor (VEGF) drugs in ophthalmology, VEGF and anti-VEGF therapy.眼科抗血管内皮生长因子（VEGF）药物时代、VEGF与抗VEGF治疗
Cent Eur J Immunol. 2016;41(3):311-316. doi: 10.5114/ceji.2016.63132. Epub 2016 Oct 25.
本文引用的文献
1
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration: Two-Year Results.雷珠单抗和贝伐单抗治疗新生血管性年龄相关性黄斑变性：两年结果。
Ophthalmology. 2020 Apr;127(4S):S135-S145. doi: 10.1016/j.ophtha.2020.01.029.
2
Topical bevacizumab for neovascular glaucoma: a pilot study.局部应用贝伐单抗治疗新生血管性青光眼：一项初步研究。
Pharmacology. 2014;93(3-4):108-12. doi: 10.1159/000358600. Epub 2014 Feb 20.
3
High-dose topical bevacizumab for corneal neovascularization.高剂量局部贝伐单抗治疗角膜新生血管。
Pharmacology. 2013;92(5-6):310-4. doi: 10.1159/000356407. Epub 2013 Dec 4.
4
Pharmacokinetics of bevacizumab after topical and intravitreal administration in human eyes.贝伐单抗经眼部局部和玻璃体内给药后的药代动力学。
Graefes Arch Clin Exp Ophthalmol. 2014 Feb;252(2):331-7. doi: 10.1007/s00417-013-2495-0. Epub 2013 Oct 31.
5
Intracameral bevacizumab as an adjunct to trabeculectomy: a 1-year prospective, randomised study.眼内注射贝伐单抗作为小梁切除术的辅助治疗：一项为期 1 年的前瞻性随机研究。
Br J Ophthalmol. 2014 Jan;98(1):73-8. doi: 10.1136/bjophthalmol-2013-303966. Epub 2013 Oct 24.
6
Age-related macular degeneration.年龄相关性黄斑变性。
Lancet. 2012 May 5;379(9827):1728-38. doi: 10.1016/S0140-6736(12)60282-7.
7
Corneal penetration of topical and subconjunctival bevacizumab.贝伐单抗滴眼和球结膜下给药的角膜穿透性。
Invest Ophthalmol Vis Sci. 2011 Nov 7;52(12):8718-23. doi: 10.1167/iovs.11-7871.
8
Ranibizumab and bevacizumab for neovascular age-related macular degeneration.雷珠单抗和贝伐单抗治疗新生血管性年龄相关性黄斑变性。
N Engl J Med. 2011 May 19;364(20):1897-908. doi: 10.1056/NEJMoa1102673. Epub 2011 Apr 28.
9
Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 medicare fee-for-service part B claims file.抗新生血管治疗年龄相关性黄斑变性的药物治疗：对 2008 年 100%的医疗保险服务费用 B 部分索赔文件的分析。
Am J Ophthalmol. 2011 May;151(5):887-895.e1. doi: 10.1016/j.ajo.2010.11.017. Epub 2011 Feb 18.
10
Corneal Melt While Using Topical Bevacizumab Eye Drops.使用局部贝伐单抗滴眼液时出现角膜溶解。
Ophthalmic Surg Lasers Imaging. 2010 Mar 9:1-3. doi: 10.3928/15428877-20100215-07.
Zotero 插件